Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise

od Sumanasuriya, Semini, De Bono, Johann
Izdano u Cold Spring Harb Perspect Med (2018)

c-MET: an exciting new target for anticancer therapy

od de Bono, Johann S., Yap, Timothy A.
Izdano 2011

Future directions in the evaluation of c-MET-driven malignancies

od de Bono, Johann S., Yap, Timothy A.
Izdano 2011

CCR new strategies: Targeting the androgen receptor signaling pathway in metastatic prostate cancer

od Attard, Gerhardt, Richards, Juliet, de Bono, Johann S
Izdano 2011

Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?

od Yap, Timothy A, Swanton, Charles, de Bono, Johann S
Izdano 2012

Reappraisal of glucocorticoids in castrate-resistant prostate cancer

od Sartor, Oliver, Parker, Christopher C, de Bono, Johann
Izdano 2014

The “Pushmi-Pullyu” of DNA REPAIR: Clinical Synthetic Lethality

od Ivy, S. Percy, de Bono, Johann, Kohn, Elise C.
Izdano u Trends Cancer (2016)

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

od de Bono, Johann S, Tolcher, Anthony W, Rowinsky, Eric K
Izdano 2003

Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies

od Attard, Gerhardt, Clark, Jeremy, Cooper, Colin S., De Bono, Johann S.
Izdano 2010

Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer

od Sharp, Adam, Welti, Jonathan, Blagg, Julian, de Bono, Johann S.
Izdano u Clin Cancer Res (2016)

The promise of circulating tumor cell analysis in cancer management

od Mateo, Joaquin, Gerlinger, Marco, Rodrigues, Daniel Nava, de Bono, Johann S
Izdano u Genome Biol (2014)

Novel Therapeutic Strategies for Metastatic Prostate Cancer in the Post-Docetaxel Setting

od Sartor, Oliver, Michels, Ross M., Massard, Christophe, de Bono, Johann Sebastian
Izdano 2011

Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer

od Papadatos-Pastos, Dionysis, Dedes, Konstantin J., de Bono, Johann S., Kaye, Stanley B.
Izdano 2011

Chromatin to clinic: The molecular rationale for PARP1 inhibitor function

od Knudsen, Karen E., de Bono, Johann S., Rubin, Mark A., Feng, Felix Y.
Izdano u Mol Cell (2015)

Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial

od Loriot, Yohann, Fizazi, Karim, de Bono, Johann S., Forer, David, Hirmand, Mohammad, Scher, Howard I.
Izdano u Cancer (2016)

SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition

od Francis, Jeffrey C., Capper, Amy, Ning, Jian, Knight, Eleanor, de Bono, Johann, Swain, Amanda
Izdano u Oncotarget (2018)

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles

od Nanou, Afroditi, Crespo, Mateus, Flohr, Penny, De Bono, Johann S., Terstappen, Leon W. M. M.
Izdano u Cancers (Basel) (2018)

AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification

od Sowalsky, Adam G., Sharp, Adam, Trostel, Shana Y., de Bono, Johann S., Plymate, Stephen R.
Izdano u Cancer Treat Res Commun (2020)

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to b...

od A’Hern Roger, DeBono Johann, Sandhu Shahneen, Kalaitzaki Eletheria, Usdin Martine, Hall Emma E
Izdano 2011-12-01

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to b...

od A’Hern, Roger, DeBono, Johann, Sandhu, Shahneen, Kalaitzaki, Eletheria, Usdin, Martine, Hall, Emma E
Izdano 2011